Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ipratropium · 1 trial · 1 indication
Forced expired volume in one second (FEV1) over 8 hours post-dose
| Arm | Type | Description |
|---|---|---|
| Salbutamol alone | ACTIVE_COMPARATOR | 200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo |
| Salbutamol and RPL554 | EXPERIMENTAL | 200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554 |
| Ipratropium | ACTIVE_COMPARATOR | Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo |
| Ipratropium and RPL554 | EXPERIMENTAL | Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554 |
| RPL554 | EXPERIMENTAL | Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554 |
| Placebo | PLACEBO_COMPARATOR | Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo |
| Name | Type | Description |
|---|---|---|
| Salbutamol | DRUG | 200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI) |
| Ipratropium | DRUG | 40 micrograms ipratropium administered using a pMDI |
| RPL554 | DRUG | 6 mg RPL554 administered using a nebuliser |
| Salbutamol matched placebo | DRUG | Placebo pMDI |
| Ipratropium matched placebo | DRUG | Placebo pMDI |
| RPL554 matched placebo | DRUG | Nebulised placebo |
Inclusion Criteria: * Provide informed consent * Males not donating sperm and using adequate contraception or females who are surgically sterile or postmenopausal * 12-lead ECG showing:Heart rate 45 to 90 bpm, QTcF≤450 msec, QRS ≤120 msec, PR interval ≤220 msec, no clinically significant abnormalit...
Ipratropium is a small molecule developed by Merck & Company, Inc. (ticker MRK) for chronic obstructive pulmonary disease, a respiratory condition. It is being studied in clinical development for COPD, and the program includes a completed Phase 2 trial conducted in the United Kingdom in adults aged 40 years and older.
Ipratropium targets CHRM3, the M3 muscarinic acetylcholine receptor. It acts as an antagonist at this receptor, meaning it blocks receptor signaling. This target class places ipratropium among antimuscarinic agents, a mechanism relevant to airway smooth muscle control in chronic obstructive pulmonary disease.
Ipratropium is developed by Merck & Company, Inc., which trades under the ticker MRK. The company is the sponsor associated with the clinical development program for this small molecule in chronic obstructive pulmonary disease, a respiratory therapeutic area.
Ipratropium is in Phase 2 clinical development for chronic obstructive pulmonary disease. It is an investigational small molecule and is not described as approved. The development program includes one completed Phase 2 trial, and no active trials are currently listed for this asset.
Ipratropium has been evaluated in the completed Phase 2 trial NCT02542254, titled The Effects of RPL554 on Top of Standard COPD Reliever Medications. That trial enrolled 36 participants with chronic obstructive pulmonary disease in the United Kingdom, was randomized, double blind, and placebo controlled, and included adults aged 40 years and older.